CliffBio
small molecule

ABSTRAL

FENTANYL CITRATE

Loss of exclusivity—loss of exclusivity
CompanySentynl Therapeutics, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameABSTRAL
Active ingredientFENTANYL CITRATE
StrengthEQ 0.4MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalJanuary 2011
Marketing statusDISCN

More from Sentynl Therapeutics, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ABSTRAL patent cliff — loss of exclusivity — | CliffBio